In line with these findings, cGAS-STING pathway was identified as a prognostic biomarker for improved clinical outcomes in hepatocellular carcinoma and non-small cell lung cancer (NSCLC) [19, 28]. This evidence concerns the gene STING1 and non-small cell lung carcinoma.